cell and gene therapy world



Our Partners

Fibreocell WorldCourier medcision trakcel
fisher bioservices Brooks SAVSU


The 2018 Supply Chain & Logistics Hub   

Ever wondered what a fully integrated, end-to-end cell or gene therapy supply chain model actually looks like?

The journey goes through a cell & gene therapy supply chain of the future! Demystify every component, from cryopreservation to product tracking, and from initial sample collection to clinical site administration. You will leave with a clear vision of what YOUR product’s optimal supply chain management model should look like through scale up to the commercial setting.



supply chain hub

You will visit seven hubs in total, representing the most important elements in the chain of custody:


1.Supply Chain Planning fibrocell
2. Registration & Workflow Management TrakCel
3. Transportation World Courier
4. Cryopreservation Brooks

5. Temperature Management

6. Point of Care Administration medcision

7. Commercialization

fisher bioservices




Each of the seven supply chain hub partners has written a never before seen case study detailing a customer challenge and how this was overcome, take a look at the featured case study...


Catch up on previous case studies

Discover More

Supply Chain logistics hub floor plan



Raw & Starting Materials: Tuesday, 23 January

Facing up to critical raw materials supply shortfalls – the single largest elephant in the commercial cell & gene therapy room? 

  • Where specifically do/will the greatest shortfalls current exist and just how significant are they in the context of expected clinical and commercial demand over the short- to mid-term? (Eg. plasmids, cell culture media)
  • How to develop the innovation and infrastructure needed to overcome raw material supply shortages whilst minimizing Cost of Goods? (Eg. capitalizing on novel/emerging cell sources for the cell therapy industry)

Starting material optimization for autologous and allogeneic cell & gene therapies

  • Viral safety considerations for cell- and gene-based therapies  
  • How to manage and standardize global/multi-site apheresis? Addressing quality and consistency challenges
  • Defining best practice in allogeneic cell therapy donor supply and management

How to maximize efficiency in raw and starting materials quality control/characterization

  • Optimizing quality of raw and starting materials – what exactly constitutes ‘good enough’? 
  • Identifying and overcoming key challenges in raw and starting materials management for decentralized/point of care manufacturing (eg. of a CAR T cell immunotherapy)?

Cold Chain & Data Integration/Management: Wednesday, 24 January 

 Supply chain data management and integration

  • Integrated approach to management of CGT product supply chain
  • How to identify the data that is really critical to collect, and how to integrate and utilize it to the benefit of the overall supply chain?
  • Scaling up to commercial: how to automate the data management piece to allow the move from hundreds to thousands of patients?
  • Track and trace and supply chain security – how to satisfy disparate regulatory requirements and standards on a multinational basis?
  • Generic ‘off the shelf’ vs. tailored cell therapy supply chain management software – analysing the practical utility/applicability of both options


Tour of the Vein-to-Vein Supply Chain Hub
This session will be staged in our expanded Supply Chain hub – an experiential, circular journey along the entirety of the autologous cell-based therapy supply chain: from starting material obtainment/management through cold chain logistics, bioprocessing, quality control, fill-finish and management/ delivery to the patient back at the point of care.

  • Delivering a strategic roadmap for supply chain development and validation for patient-specific cell & gene therapies
  • How to identify/predict and minimize the potential variables in your supply chain to achieve true consistency in product quality and delivery?
  • Leveraging supply chain strategies and technology to scale from clinical to commercial volumes

Supply chain scale up strategies and enabling technologies to minimize CoGs

  • Sector leaders’ tips for designing and implementing efficient, scalable
  • cell & gene supply chains
  • Next generation cold chain technologies (including automated/closed solutions) – what real improvements are they delivering in practice? (Eg. cost, quality, configurability, flexibility and ease of integration)

  • "The event reflected the fantastic growing enthusiasm around cell and gene therapy, including small and large companies, investors and regulators. It was great to see everyone so engaged and so positive. The event really gives you the “pulse” of what is happening right now in cell and gene therapy."
    Anne-Virginie Eggimann,
  • “Great program, great people, great venue.”
    Klaus Kühlcke
    Managing Director, EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.”
    Nathalie Clement
    Associate Director, Powell Gene Therapy Center, University of Florida
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • "It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives."
    Kurt Gielen
    Acquisition & Business Development Manager, BioMedical Materials, Chemelot Campus B.V.
  • “Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.”
    Steven Goodman
    Director, Strategy and Engagement, GSK